Shareholders Equity: The sum of preferred and common equity items.
Ovid Therapeutics (OVID) had Shareholders Equity of $59.28M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.13M |
|
$-10.23M |
|
-- |
|
$0.13M |
|
$12.68M |
|
$-12.55M |
|
$2.31M |
|
$-10.23M |
|
$-10.23M |
|
$-10.23M |
|
$-10.23M |
|
$-10.23M |
|
$-10.23M |
|
$-12.55M |
|
$-12.41M |
|
71.05M |
|
71.05M |
|
$-0.14 |
|
$-0.14 |
|
| Balance Sheet Financials | |
$45.92M |
|
$0.35M |
|
$35.73M |
|
$81.65M |
|
$9.31M |
|
$13.07M |
|
$13.07M |
|
$22.38M |
|
$59.28M |
|
$59.28M |
|
|
Shareholders Equity |
$59.28M |
71.11M |
|
| Cash Flow Statement Financials | |
$-10.28M |
|
$5.10M |
|
$0.01M |
|
$28.23M |
|
$23.07M |
|
$-5.17M |
|
$1.28M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.93 |
|
-- |
|
-- |
|
0.18 |
|
0.24 |
|
100.00% |
|
-9653.85% |
|
-9653.85% |
|
-- |
|
-7873.08% |
|
-7873.08% |
|
$-10.28M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-17.27% |
|
-17.27% |
|
-12.53% |
|
-14.15% |
|
$0.83 |
|
$-0.14 |
|
$-0.14 |
|